Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Paclitaxel in Combination With Bevacizumab in Patients With Stage IV NSCLC. (AVATAX)

20 de novembro de 2020 atualizado por: Centre Hospitalier Annecy Genevois

Retrospective Multicenter Study of Paclitaxel in Combination With Bevacizumab in Patients With Stage IV Non-small Cell Lung Cancer (NSCLC).

The aim of the study is to evaluate the paclitaxel-bevacizumab combination retrospectively and multicenter in current practice, with subgroup analyses of the following patients: patients who have previously received immunotherapy, patients with an EGFR or ALK oncogenic addiction pathway, patients who have previously received taxanes or anti-angiogenic agents.

Visão geral do estudo

Status

Concluído

Descrição detalhada

Lung and bronchopulmonary cancer is the leading cause of cancer death in France and worldwide. It is diagnosed at the metastatic stage from the outset in approximately 50% of cases. Non-small cell lung cancers (NSCLC) are the most frequent histological forms of lung cancer (approximately 85% of cases) with a predominance of the non-epidermal type.

The increase in the number of treatments available, improved supportive care and better patient selection have, in recent years, made it possible to expand the range of first-line chemotherapy treatments available at delà̀ and have contributed to the increase in overall survival (OS). As a result, nearly 80% of patients with metastatic NSCLC receive a second line of treatment. The main objective in these often symptomatic patients is a satisfactory tumor control rate with acceptable tolerability.

For a long time, the second-line reference chemotherapy has been docetaxel or pemetrexed as monotherapy with modest results. Alternative treatments such as the combination of paclitaxel (chemotherapy)-bevacizumab (anti-angiogenic monoclonal antibody) have been studied. Since 2010, by analogy with breast cancer and in the absence of therapeutic alternatives, the paclitaxel-bevacizumab doublet has been used in non-epidermal stage IV NSCLC in France. The value of combining taxane chemotherapy with an anti-angiogenic molecule has been demonstrated in two Phase 3 clinical trials. Thus, this combination is an integral part of the possible treatments in 2nd line and beyond, registered since 2016 in the treatment guidelines for non-epidermal NSCLC.

The first-line therapeutic strategy will also be redefined in 2019 with the use of immunotherapy for a majority of patients. Subsequent treatment lines will be modified, with a focus on chemotherapy, in particular the paclitaxel-bevacizumab combination.

As this combination has been used in current practice for several years, and in view of the upcoming changes to the first and second line of NSCLC treatment, data on the efficacy and tolerance of this combination in real life are needed to guide our practices. Recent studies are also looking at the efficacy of chemotherapy, particularly taxane chemotherapy associated with an anti-angiogenic agent after a previous line including immunotherapy, with a favorable signal.

The aim of the study is to evaluate the paclitaxel-bevacizumab combination retrospectively and multicenter in current practice, with subgroup analyses of the following patients: patients who have previously received immunotherapy, patients with an EGFR or ALK oncogenic addiction pathway, patients who have previously received taxanes or anti-angiogenic agents.

Tipo de estudo

Observacional

Inscrição (Real)

320

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Boulogne Billancourt, França
        • Hopital Ambroise Pare Ap-Hp
      • Brest, França
        • Centre Hospitalier Universitaire Brest
      • Chambéry, França
        • Centre Hospitalier Metropole Savoie
      • Créteil, França
        • Centre Hospitalier Intercommunal de Créteil
      • Grenoble, França
        • Centre Hospitalier Universitaire Grenoble Alpes
      • Le Chesnay, França
        • Centre Hospitalier de Versailles André Mignot
      • Lille, França
        • Centre Hospitalier Universitaire de Lille
      • Lyon, França
        • Hospices Civils de Lyon
      • Lyon, França
        • Centre Leon Berard Lyon
      • Mantes-la-Jolie, França
        • Centre Hospitalier François Quesnay
      • Metz-Tessy, França, 74374
        • Centre Hospitalier Annecy Genevois
      • Paris, França
        • Institut Curie
      • Saint-Cloud, França
        • Institut Curie Saint Cloud
      • Saint-Étienne, França
        • Institut de Cancérologie Lucien Neuwirth
      • Suresnes, França
        • Hôpital Foch

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra de Probabilidade

População do estudo

The study will include all eligible patients who started paclitaxel-bevacizumab between January 1, 2010 and May 1, 2018. The number of patients is estimated to be approximately 200.

Descrição

Inclusion Criteria:

  • At least 18 years old;
  • Histologically or cytologically confirmed diagnosis of non-epidermal NSCLC;
  • Advanced stage IV disease at the start of treatment with paclitaxel-bevacizumab according to TNM 7/8th edition classification;
  • Treatment with paclitaxel-bevacizumab received as second-line therapy or beyond, in a clinical trial or not;
  • Alive patients not opposed to the use of their data

Exclusion Criteria:

  • Patient under guardianship or curatorship at the date of the study ;
  • Patients alive at the time of the study who are opposed to the use of their data
  • Opposition to the use of their data expressed during the lifetime of patients who died at the time of the study.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Progression-free survival
Prazo: Up to 12 months
Progression-free survival with paclitaxel-bevacizumab, i.e., the time from the start of paclitaxel-bevacizumab treatment to cancer progression, estimated at 12 months in the general population.
Up to 12 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Drugs administration dosage description
Prazo: Up to 12 months
Description of the different monthly drug administration regimens
Up to 12 months
Objective response rate and control rate
Prazo: Up to 12 months
Objective response rate and control rate according to RECIST 1.1 criteria in the general population
Up to 12 months
Overall survival Rate
Prazo: Up to 12 months
Overall survival, assessed on the whole population
Up to 12 months
Objective Response Rate
Prazo: Up to 12 months

Objective Response Rate in the following subgroups:

  • patients treated after immunotherapy and especially immediately after immunotherapy;
  • Patients with an oncogenic EGFR or ALK addiction pathway;
  • Patients previously treated with taxanes;
  • Patients previously treated with anti-angiogenic drugs;
Up to 12 months
Progression-Free Survival Rate
Prazo: Up to 12 months

Progression-Free Survival in the following subgroups:

  • patients treated after immunotherapy and especially immediately after immunotherapy;
  • Patients with an oncogenic EGFR or ALK addiction pathway;
  • Patients previously treated with taxanes;
  • Patients previously treated with anti-angiogenic drugs;
Up to 12 months
Disease Control Rate
Prazo: Up to 12 months

Disease Control in the following subgroups:

  • patients treated after immunotherapy and especially immediately after immunotherapy;
  • Patients with an oncogenic EGFR or ALK addiction pathway;
  • Patients previously treated with taxanes;
  • Patients previously treated with anti-angiogenic drugs;
Up to 12 months
Overall Survival Rate
Prazo: Up to 12 months

Overall Survival in the following subgroups:

  • Patients treated after immunotherapy and especially immediately after immunotherapy;
  • Patients with an oncogenic EGFR or ALK addiction pathway;
  • Patients previously treated with taxanes;
  • Patients previously treated with anti-angiogenic drugs;
Up to 12 months
Frequency of safety events
Prazo: Up to 12 months
Frequency of grade ≥3 adverse events and frequency of discontinuation of paclitaxel-bevacizumab for toxicity ;
Up to 12 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Chantal Decroisette, CH Annecy Genevois

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de outubro de 2019

Conclusão Primária (Real)

5 de junho de 2020

Conclusão do estudo (Real)

5 de junho de 2020

Datas de inscrição no estudo

Enviado pela primeira vez

9 de novembro de 2020

Enviado pela primeira vez que atendeu aos critérios de CQ

20 de novembro de 2020

Primeira postagem (Real)

23 de novembro de 2020

Atualizações de registro de estudo

Última Atualização Postada (Real)

23 de novembro de 2020

Última atualização enviada que atendeu aos critérios de controle de qualidade

20 de novembro de 2020

Última verificação

1 de novembro de 2020

Mais Informações

Termos relacionados a este estudo

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever